视黄酸驱动CD16hiCD177+中性粒细胞扩增介导激素抵抗性胃肠道GVHD
该研究通过单细胞RNA测序发现,在激素抵抗性胃肠道移植物抗宿主病(SR-GI-GVHD)患者血液中CD16hiCD177+中性粒细胞亚群显著扩增。该亚群经CD177与内皮CD31结合迁移至肠道,通过MyD88感知肠道细菌释放NETs导致上皮损伤。视黄酸(RA)通过RARA-SPI1转录轴驱动该亚群扩增和致病编程,药物抑制RARA可改善小鼠GI-GVHD并恢复激素敏感性。
要点
- SR-GI-GVHD患者血液中CD16hiCD177+中性粒细胞亚群显著扩增
- RA通过RARA-SPI1轴驱动该亚群扩增和致病编程
- 抑制RARA可改善小鼠GI-GVHD并恢复皮质激素敏感性
核心结论
- RA驱动的CD177+中性粒细胞亚群是SR-GI-GVHD的关键介质,RARA抑制是有前景的治疗策略。
研究设计与样本
- 基于患者血液单细胞RNA测序的机制研究,并在小鼠GVHD模型中验证遗传删除和药物抑制。
主要发现
- CD16hiCD177+中性粒细胞亚群在SR-GI-GVHD患者血液中显著扩增,通过CD177结合内皮CD31迁移至肠道。
- 该亚群经MyD88感知肠道细菌后释放NETs,直接导致上皮损伤。
- 患者中升高的视黄酸通过RARA-SPI1转录轴驱动该亚群扩增和致病编程。
- 小鼠GVHD模型中供体细胞Cd177或Myd88遗传删除可减轻疾病。
- AGN193109药物抑制RARA可改善GI-GVHD、提高生存率并恢复皮质激素敏感性。
临床怎么用
- RARA抑制(如AGN193109)可能作为SR-GI-GVHD的治疗策略,并恢复皮质激素敏感性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Steroid-resistant gastrointestinal graft-versus-host disease (SR-GI-GVHD) is a lethal complication of allogeneic hematopoietic stem cell transplantation with no clear therapeutic target. The role of neutrophil heterogeneity in its pathogenesis remains poorly defined. Through single-cell RNA sequencing of patient blood, we identified a specific neutrophil subset (CD16hiCD177+) that is markedly expanded in SR-GI-GVHD. This subset uses CD177 to bind endothelial CD31, facilitating transmigration into the intestine. Upon arrival, MyD88-mediated sensing of translocated gut bacteria triggers the release of neutrophil extracellular traps (NETs), directly causing epithelial damage. Mechanistically, we found that elevated levels of retinoic acid (RA) in patients drive the expansion and pathogenic programming of these neutrophils via the retinoic acid receptor α-Spi-1 proto-oncogene (RARA-SPI1) transcriptional axis. In a murine model of GVHD, genetic deletion of Cd177 or Myd88 in donor cells attenuated disease. Crucially, pharmacological inhibition of the RA receptor with AGN193109 not only ameliorated GI-GVHD and improved survival but also restored sensitivity to corticosteroids. Together, these findings delineate a complete pathogenic circuit, from the metabolic driver RA and the RARA-SPI1 transcriptional axis to the CD177+ neutrophil cellular effector and its NET formation-mediated tissue damage. This establishes the RA-driven CD177+ neutrophil subset as a key mediator of SR-GI-GVHD and identifies RARA inhibition as a promising therapeutic strategy.
引用
- Liang W, Xu D, Zhang L, et al. Retinoic acid-driven expansion of CD16hiCD177+ neutrophils mediates steroid-resistant GI-GVHD. Blood. 2026. PMID: 42322118. doi:10.1182/blood.2025032193
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。